AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00980460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02020408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]raclopride
Description: 1.\[11C\]raclopride -The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
Study NCT02020408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]DASB
Description: BPND of \[11C\]DASB.
Study NCT02020408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amphetamine
Description: The change (Δ) in BPND (the difference between the \[11C\]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
Study NCT03479710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT infusion
Description: Fecal microbiota transplantation via OGD
Study NCT01961063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT01961063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells
Description: Given IV
Study NCT01961063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01961063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00258934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated, split-virion influenza vaccine
Description: 0.1 mL single annual dose
Study NCT00258934 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated, split-virion, influenza virus
Description: 0.5 mL single annual dose
Study NCT01631396 — intervention group
Intervention type: DRUG
Intervention: Sugammadex vs. Neostigmine
Description: * Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~* Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
Study NCT01616368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating and Living Course
Description: An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
Study NCT01925248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
Study NCT01925248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
Study NCT02620488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery
Description: Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
Study NCT02620488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
Study NCT03347084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excitation
Description: Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Study NCT00147316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: 0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
Study NCT02978950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound surveillance
Description: bilateral lower extremity venous duplex
Study NCT02978950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No ultrasound surveillance
Description: will have daily exam and history as per normal clinical routine
Study NCT02646813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraluminal Placement
Description: Pt. will have Arndt Endobronchial Blocker placed intraluminally
Study NCT00980460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: Undergo liver transplant
Study NCT00311597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: single fractionated radiation therapy
Study NCT00398866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synvisc (Hylan G-F20; hyaluronan injection)
Description: 1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
Study NCT00398866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine (local anesthesia injection)
Description: 1 ml of bupivicaine 0.5% injected once a week for 2 weeks
Study NCT00980460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT00980460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT00980460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03347084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhibition
Description: Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
Study NCT03443921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Artery Divestment Technique
Description: Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
Study NCT03443921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
Study NCT00398866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog (triamcinolone; corticosteroid injection)
Description: 1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
Study NCT02646813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraluminal Placement
Description: Pt. will have Arndt Endobronchial Blocker placed extraluminally
Study NCT00852501 — intervention group
Intervention type: OTHER
Intervention: To perform RT-PCR on the tissue obtained during surgery
Description: The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
Study NCT02925403 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21/Matrix-M1
Study NCT02925403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03395457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Application of usual pharmacological care for chronic migraine
Study NCT03395457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: Application of usual pharmacological care for chronic migraine
Study NCT03395457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: 5 sessions of manual therapy over 12 weeks
Study NCT03912935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comparison between two different intubating position
Description: Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
Study NCT05296174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive-oriented intervention program
Description: The experimental group was offered six 40-minute courses once a week.
Study NCT05296174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education activities program
Description: The control group was offered health education activities once a week.
Study NCT02396511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TRC105
Description: weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
Study NCT02396511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
Study NCT05088850 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00711880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study NCT00711880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study NCT00810511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A contact lens
Description: Silicone hydrogel contact lens
Study NCT00810511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lens
Description: Silicone hydrogel contact lens
Study NCT04323943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Foot orthosis (AFO)
Description: The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed
Study NCT04323943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Foot orthosis (AFO)
Description: The experimental protocol will require 4 visits: one inclusion visit and 3 visits for evaluations. Each visit corresponds to one condition: C-AFO, CM-AFO or NO (according to a random order).~Visit #1 will consist in a clinical evaluation and a familiarization session with the measuring devices and methodologies used in visit#2 #3 and #4.~During #2, #3 and #4 visits (14 days between each session), the subject will perform with C-AFO, CM-AFO or NO according to the random order :~* 5 x 15m overground at a comfortable walking speed (CWS) where EMG, ground reaction force and kinematics will be measured~* 6MWT where energy cost will be measured~* 5 x 15m overground (immediately after the 6MWT) at a comfortable walking speed
Study NCT02587078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volulyte
Description: Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
Study NCT02587078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Jonosteril
Description: Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
Study NCT00734058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser MAZE by Ablation of Cardiac Tissue
Description: The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
Study NCT03576664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 25mg
Description: Cross-over, randomized, placebo-controlled study.
Study NCT00602732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Reach Out for a Safe Environment (ROSE) program
Description: Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
Study NCT00602732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced care as usual (ECU)
Description: Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
Study NCT04334876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARS-CoV-2 IgG Antibody Testing Kit
Description: A, finger prick, at home test for SARS-CoV-2 IgG Antibodies.
Study NCT03782389 — intervention group
Intervention type: OTHER
Intervention: Preseason Periodic Health Examination Completion
Description: all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
Study NCT00981266 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Spectra/Becker 80 Breast Implant
Description: The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
Study NCT04322799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: Randomization between prosthetic components
Description: Patients are randomized between two types of cup components in total hip arthroplasty. Identical cups made of either highly-crosslinked polyethylene or conventional polyethylene.
Study NCT04034225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-301
Description: Day 0, Week 3, Week 6, Week 9 then every 6 weeks (±3 days) for 6 additional doses, thereafter every 12 weeks (±3 days) up to 24 months.
Study NCT04034225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months or Pembrolizumab (400 mg dose) IV will be administered over 30 minutes every 6 weeks up to 24 months.
Study NCT02240901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway（LMA）
Description: Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
Study NCT02240901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation（ETI）
Description: Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
Study NCT01071902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT01071902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT01071902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT01071902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT01071902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT01071902 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT01111331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 25 mg
Description: 25 mg BI 10773 qd for 5 days
Study NCT01111331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 25 mg
Description: 25 mg Warfarin single dose
Study NCT01111331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 25 mg
Description: 25 mg BI 10773 qd for 12 days
Study NCT01111331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: 25 mg warfarin single dose with and without 50 mg BI 10773
Study NCT03428490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fully integrated treatment
Description: Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
Study NCT03428490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stand-alone Intensive Outpatient Program
Description: Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
Study NCT04065412 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laryngeal handshake technique
Description: The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
Study NCT04457609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Current standardized treatment for Covid-19
Study NCT04457609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Current standardized treatment for Covid-19
Study NCT04457609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Adjuvant therapy on top of current standardized treatment (Oseltamivir + Azithromycin)
Study NCT03576664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Cross-over, randomized, placebo-controlled study.
Study NCT01491191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide
Description: Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
Study NCT01491191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
Study NCT02649569 — intervention group
Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wear activity monitor
Study NCT02649569 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30